InSite Vision Inc. (INSV.OB) Awarded Therapeutic Discovery Project Grant
InSite Vision Inc. announced yesterday that they will receive $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program. The grant was awarded in recognition of two clinical-stage programs. One is ISV-502, a product candidate being developed for the treatment of blepharitis. The other is ISV-303; a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. The QTDP credit is available to biotechnology companies who are conducting studies or carrying out research for the purpose of securing approval from the U.S. Food and Drug Administration for products that address an area of unmet medical…